Exploring the potential of new ligand (-3-((4-(4-((-1,2-diphenyl-2-(thiazol-2-ylimino) ethylidene) amino) benzyl) phenyl) imino) butan-2-mono (PTIEABPBO) type imine-oxime complex with palladium (II) as an anticancer drug

Herein, a new imine-oxime ligand was synthesized in a two-step reaction. In the first step, 2-aminothiazole and benzil were reacted with glacial acetic acid as a catalyst resulting in the formation of 1,2-diphenyl-2-(thiazol-2-ylimino)ethan-1-one. In the second step, this intermediate was then reacted with diacetyl monoxime and 4,4'-methylenedianiline for synthesis of target ligand, PTIEABPBO. Afterwards, a palladium (II) complex of this ligand was also synthesized. Analyses of ligand and its complex were carried out via FT-IR, UV-Vis, and ¹H, ¹³C-NMR, analysis of melting point, elemental analysis, FESEM, and XRD. Findings of morphological study confirmed the purity of the synthesized compounds by demonstrating close agreement between calculated and experimental values. FT-IR highlights presence of azomethine and oxime bands in ligand, with shifts observed upon complexation with palladium. Crystallographic study indicated a crystalline, nanoscale structure for both compounds. Finally, biological evaluation demonstrated significant inhibitory activity of synthesized compounds against MCF-7 breast cancer cell line, when compared against HEK-293 normal cell line.